Ikena Oncology (IKNA) Stock Price, News & Analysis

Company Overview

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $1.50 to $1.55
• 50-Day Range: $1.49 to $1.76
• 52-Week Range: $1.22 to $1.94
• Volume: 38,079 shs
• Average Volume: 434,641 shs
• Market Capitalization: $72.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

Ikena Oncology Stock Analysis - MarketRank™

Ikena Oncology scored higher than 49% of companies evaluated by MarketBeat, and ranked 623rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ikena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ikena Oncology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ikena Oncology are expected to grow in the coming year, from ($0.91) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ikena Oncology is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ikena Oncology is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ikena Oncology has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.48% of the float of Ikena Oncology has been sold short.

Short Interest Ratio / Days to Cover

Ikena Oncology has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ikena Oncology has recently increased by 41.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ikena Oncology does not currently pay a dividend.

Dividend Growth

Ikena Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.48% of the float of Ikena Oncology has been sold short.

Short Interest Ratio / Days to Cover

Ikena Oncology has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ikena Oncology has recently increased by 41.10%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Ikena Oncology has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ikena Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.94% of the stock of Ikena Oncology is held by insiders.

Percentage Held by Institutions

75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IKNA Stock Analysis - Frequently Asked Questions

How have IKNA shares performed this year?

Ikena Oncology's stock was trading at $1.64 at the beginning of 2025. Since then, IKNA shares have decreased by 8.5% and is now trading at $1.50.
View the best growth stocks for 2025 here.

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08.

When did Ikena Oncology IPO?

Ikena Oncology (IKNA) raised $125 million in an initial public offering on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO.

How do I buy shares of Ikena Oncology?

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ikena Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ikena Oncology investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 3/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IKNA
• CUSIP: N/A
• CIK: 1835579
• Web: ikenaoncology.com
• Phone: 857-273-8343
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +100.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-68,170,000.00
• Net Margins: N/A
• Pretax Margin: -9,067.17%
• Return on Equity: -36.88%
• Return on Assets: -33.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.32
• Quick Ratio: 15.32

Sales & Book Value

• Annual Sales: $9.16 million
• Price / Sales: 7.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.52 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 48,260,000
• Free Float: 45,391,000
• Market Cap: $72.39 million
• Optionable: Not Optionable
• Beta: 0.49